Get the Stockscreener App
6.68
1.18%
-0.08
After Hours:
6.55
-0.13
-1.95%
Cartesian Therapeutics Inc stock is traded at $6.68, with a volume of 157.04K.
It is down -1.18% in the last 24 hours and down -12.11% over the past month.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
See More
Previous Close:
$6.76
Open:
$6.72
24h Volume:
157.04K
Relative Volume:
1.02
Market Cap:
$173.70M
Revenue:
$26.00M
Net Income/Loss:
$-219.71M
P/E Ratio:
-0.1341
EPS:
-49.8
Net Cash Flow:
$-51.37M
1W Performance:
-7.48%
1M Performance:
-12.11%
6M Performance:
-41.71%
1Y Performance:
-66.40%
1-Day Range:
$6.4793
$6.8818
1-Week Range:
$6.40
$7.25
52-Week Range:
$5.98
$20.12
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Name
Cartesian Therapeutics Inc
Sector
Industry
Phone
301-348-8698
Address
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
6.68 | 175.78M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Wedbush | Outperform |
| Dec-19-24 | Initiated | BTIG Research | Buy |
| Aug-06-24 | Initiated | TD Cowen | Buy |
| Jul-02-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-04-24 | Initiated | Oppenheimer | Outperform |
| May-24-24 | Initiated | Mizuho | Buy |
| Apr-23-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-23-24 | Initiated | Leerink Partners | Outperform |
| Aug-18-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Jun-14-22 | Reiterated | Needham | Buy |
| Jun-06-22 | Initiated | SVB Leerink | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jan-26-21 | Upgrade | Mizuho | Neutral → Buy |
| Oct-01-20 | Downgrade | Mizuho | Buy → Neutral |
| Oct-01-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-12-20 | Downgrade | Stifel | Buy → Hold |
| Apr-28-20 | Initiated | H.C. Wainwright | Buy |
| Jan-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-20 | Initiated | William Blair | Outperform |
| Jun-27-18 | Initiated | Janney | Buy |
| Mar-30-17 | Reiterated | UBS | Buy |
View All
Cartesian Therapeutics Inc Stock (RNAC) Latest News
Does Cartesian Therapeutics Inc. stock trade at a discount to peersChart Signals & Daily Volume Surge Signals - Улправда
Why Cartesian Therapeutics Inc. stock is a value investor pickBear Alert & Proven Capital Preservation Methods - Улправда
What catalysts could drive Cartesian Therapeutics Inc. stock higherChart Signals & Daily Volume Surge Signals - Улправда
Is Cartesian Therapeutics Inc. stock a buy before product launchesWeekly Investment Report & Weekly High Return Forecasts - Улправда
Aug Wrap: Why Cartesian Therapeutics Inc. (1S70) stock could be top winnerWeekly Gains Summary & Daily Volume Surge Trade Alerts - DonanımHaber
Can Cartesian Therapeutics Inc. stock maintain growth trajectoryQuarterly Market Review & AI Driven Stock Movement Reports - DonanımHaber
Earnings Recap: How Cartesian Therapeutics Inc. stock trades during market volatilityJuly 2025 Chart Watch & Reliable Breakout Forecasts - DonanımHaber
Cartesian Therapeutics Appoints Adrian Bot to Board of Directors - citybiz
How Cartesian Therapeutics Inc. stock performs in interest rate cyclesDay Trade & Expert Curated Trade Ideas - Улправда
Is Cartesian Therapeutics Inc. stock in correction or buying zoneMarket Activity Report & Community Trade Idea Sharing - Улправда
Cartesian Therapeutics Appoints Dr. Adrian Bot to Board of Directors - Quiver Quantitative
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors - The Manila Times
Will Cartesian Therapeutics Inc. stock deliver better than expected guidanceJuly 2025 Technicals & Low Risk Growth Stock Ideas - Улправда
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics Earnings Notes - Trefis
683 Capital Management LLC Grows Stock Holdings in Cartesian Therapeutics, Inc. $RNAC - Defense World
Independent Director of Cartesian Therapeutics Picks Up 168% More Stock - simplywall.st
Cartesian Therapeutics (RNAC) Sees Share Boost After Insider Pur - GuruFocus
Cartesian stock rebounds after insider buy (RNAC:NASDAQ) - Seeking Alpha
Cartesian Therapeutics Director Purchases 30,000 Shares - TradingView — Track All Markets
Can Cartesian Therapeutics Stock Recover If Markets Fall? - Trefis
Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation - Yahoo Finance
What MACD trends signal for Cartesian Therapeutics Inc. (1S70) stockPortfolio Return Summary & Reliable Volume Spike Alerts - Newser
Why Cartesian Therapeutics Inc. (1S70) stock stays undervaluedJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Weekly Earnings: What is the fair value estimate for Cartesian Therapeutics Inc 1S70 stock in 20252025 AllTime Highs & Reliable Volume Spike Trade Alerts - BỘ NỘI VỤ
What is the fair value estimate for Cartesian Therapeutics Inc. (1S70) stock in 2025Bond Market & Verified Momentum Stock Watchlist - Newser
Is Cartesian Therapeutics Inc. (1S70) stock a buy for dividend portfoliosEarnings Trend Report & Weekly Stock Breakout Alerts - Newser
Is Cartesian Therapeutics Inc. stock cheap at current valuationEarnings Growth Report & Real-Time Volume Analysis - Newser
Will Cartesian Therapeutics Inc. (1S70) stock outperform global peers2025 Big Picture & Technical Entry and Exit Alerts - Newser
What makes Cartesian Therapeutics Inc. (1S70) stock appealing to growth investorsQuarterly Profit Review & High Accuracy Buy Signal Tips - Newser
Why Cartesian Therapeutics Inc. (1S70) stock remains stableEarnings Risk Report & Community Driven Trade Alerts - Newser
Cartesian Therapeutics, Inc. (RNAC) 7.5% in After-hours: Amid Routine Trading Conditions - Stocks Telegraph
Free cash flow per share of Cartesian Therapeutics, Inc. – MUN:1S70 - TradingView
Book value per share of Cartesian Therapeutics, Inc. – MUN:1S70 - TradingView
Is Umiya Tubes Limited Stock Risky in the Current Market EnvironmentInsider Selling Patterns & High Return Capital Gains - earlytimes.in
Automated Systems Holdings Limited Announces Change in Share Registrar - The Globe and Mail
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $38.00 - Defense World
Acute Respiratory Distress Syndrome Pipeline Drugs Landscape - openPR.com
Will Cartesian Therapeutics Inc. (1S70) stock outperform energy sector in 2025July 2025 Levels & Weekly High Conviction Ideas - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock attract long term capital inflowsBear Alert & Daily Price Action Insights - newser.com
Is Cartesian Therapeutics Inc. stock a defensive play in 2025July 2025 Snapshot & Target Return Focused Picks - newser.com
How Cartesian Therapeutics Inc. (1S70) stock trades in high volatilityTrade Analysis Report & Risk Managed Trade Strategies - newser.com
Will Cartesian Therapeutics Inc. (1S70) stock recover faster than industryWeekly Stock Analysis & Low Risk Growth Stock Ideas - newser.com
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Cartesian Therapeutics Inc Stock (RNAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):